- Home
- AIRS vs INBX Comparison
AIRS vs INBX Comparison
Compare AIRS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRS | INBX |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.3M | 430.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AIRS | INBX |
|---|---|---|
| Price | $2.16 | $85.23 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $3.75 | N/A |
| AVG Volume (30 Days) | ★ 814.0K | 237.4K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $157,554,000.00 | $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | $2.78 | $230.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.53 | $10.81 |
| 52 Week High | $12.00 | $94.47 |
Technical Indicators
Market Signals| Indicator | AIRS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 23.12 | 59.17 |
| Support Level | $2.69 | $74.80 |
| Resistance Level | $3.13 | $94.47 |
| Average True Range (ATR) | 0.31 | 6.36 |
| MACD | 0.09 | -1.27 |
| Stochastic Oscillator | 1.92 | 62.68 |
Price Performance
Historical ComparisonAbout AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.